Valneva

As global temperatures continue to rise, so does the emerging threat of mosquito-borne diseases. With mosquitos now thriving in more regions, diseases like Chikungunya, Dengue, and West Nile virus are becoming widespread. Whether you are traveling to Europe, Asia, or the Americas, understanding how to help protect yourself is important. Read our latest blog by Dr. Juan Carlos Jaramillo, our Chief Medical Officer, to learn more about the growing risk of mosquito-borne diseases and essential tips for prevention and preparation. https://rb.gy/4zm1or #MosquitoBorneDiseases #infectiousdisease #climatechange #publichealth #AdvancingVaccinesForBetterLives

📍 We're in Seoul, South Korea, at the International Society of Vaccines Annual Congress! Valneva is represented by VP Clinical Development Susanne Eder-Lingelbach who is presenting on the two-year antibody persistence and safety data of our single-dose chikungunya vaccine. Details here: https://ow.ly/vYRR50TRktb #InfectiousDiseases #MosquitoBorneDiseases #AdvancingVaccinesForBetterLives

📢 In Case You Missed It! On October 10th, Valneva held its Investor Day in New York City, where CEO Thomas Lingelbach, CFO Peter Bühler, and other members of the senior leadership team laid out the Company’s key value drivers for the next 12-18 months and beyond. Key highlights included: Valneva's substantial progress on its Lyme disease vaccine candidate, led by partner Pfizer, further updates on the Company’s promising R&D pipeline and exciting growth opportunities in its commercial vaccine business. The webcast is now available for replay: https://ow.ly/3fjX50TPL7w #AdvancingVaccinesForBetterLives #InvestorDay

Valneva to Present on Chikungunya at Several Leading Scientific Conferences https://ow.ly/n0SN50TPSH8

We’re proud to announce that the Journal of Travel Medicine has published a pooled safety evaluation for Valneva’s new single-shot live-attenuated chikungunya vaccine. Read more here: https://ow.ly/TiNj50TPBpO

Up next in our #EmployeeSpotlight series – meet Michael!   As a Quality Control Laboratory Technician, Michael is responsible for delivering precise and reliable data – a high-stress, yet vital, task in ensuring our vaccines meet the required standards throughout their life cycle. Our lab technicians form part of the backbone of our mission to advance vaccines for infectious diseases with significant unmet medical need. Check out our interview with Michael to learn more about his role here at Valneva. #AdvancingVaccinesForBetterLives

Valneva and LimmaTech Awarded FDA Fast Track Designation for Tetravalent Shigella Vaccine Candidate S4V https://ow.ly/bgcz50TMMxK

This International Infection Prevention Week we’re highlighting the vital role of Infection Preventionists (IPs) in “Moving the Needle” on infection prevention. IPs are the unsung heroes working to keep the public healthy and safe, particularly from healthcare-associated infections and many other infectious threats. They develop, implement, and monitor protocols to prevent infections in healthcare settings, and educate both staff and patients about effective prevention practices. Many IPs also help advocate for vaccination, an effective tool to combat the spread of infectious diseases and prevent further outbreaks. Join us this week in honoring the tireless efforts of IPs to keep our communities safe! #IIPW #infectionprevention #vaccines #publichealth #MovingTheNeedle #AdvancingVaccinesForBetterLives

Valneva Hosts Investor Day in New York City today at 10 am ET / 4pm CET To register for the live event and webcast click here: https://ow.ly/rU2Q50TIuUS https://lnkd.in/dPbcKEsg

Valneva’s Board of Directors and Executive Committee recently visited its state-of-the-art Almeida Building in Scotland, UK for its regular meeting. Board members' received a tour of the facilities and met with the award-winning teams based on site, learning more about the manufacturing processes and taking in some of the most secure and advanced biotech facilities in Europe.